The AI Security & Governance Architect is a senior individual contributor role within IQVIA’s Security Architecture team. Artificial intelligence and generative AI are transforming how IQVIA operates — from developer productivity and business workflows to data analytics and clinical innovation. As adoption accelerates across the enterprise, the security organization must scale its ability to govern, assess, and enable that adoption responsibly and at pace.
This role sits within a broader AI security strategy function and reports to the Security Architecture leader responsible for IQVIA’s enterprise AI security direction. The AI Security & Governance Architect is instrumental in executing and maturing that strategy: working directly with development teams, the Data Office, and business units across IQVIA’s global operations to embed security and governance into AI adoption — asking the right questions, establishing the right workflows, and maintaining the visibility and control the organization needs as AI use scales.
IQVIA has existing AI governance committees and taskforces in place. This role is not a greenfield build, but the pace of AI adoption across the business demands a significant step-up in program maturity, coverage, and consistency. The AI Security & Governance Architect will be central to that effort — owning key governance and assessment workstreams, representing Security Architecture in cross-functional forums, and ensuring that as IQVIA scales its use of technologies such as Microsoft Copilot, Claude, and other leading generative AI platforms, it does so with the appropriate security controls, governance frameworks, and architectural guardrails in place.
You will sit within the global Information Security organization, with close working relationships across Security Architecture, Cloud Security, Application Security, the Data Office, Legal, Privacy, Compliance, and business units spanning IQVIA’s global operations.

Principal responsibilities will include:

•   Contribute to and help execute IQVIA’s AI security strategy, providing hands-on program delivery across governance, risk assessment, and stakeholder engagement workstreams under the direction of the Security Architecture AI lead.
•   Act as a primary security architecture partner for business units, development teams, and the Data Office as they evaluate, adopt, and scale generative AI tools and platforms — including productivity and developer assistance tools, enterprise AI platforms, and AI-enabled workflows — ensuring security requirements are understood and addressed from the outset.
•   Own and operate the AI security intake and review process for new generative AI platform and tool requests, conducting structured security assessments that evaluate vendor security posture, data handling and residency practices, telemetry and logging controls, and acceptable use implications before organizational adoption is approved.
•   Represent Security Architecture in IQVIA’s existing AI governance committees and taskforces, ensuring security risk positions, architectural guardrails, and governance requirements are embedded in decisions and communicated consistently across the organization.
•   Develop, maintain, and operationalize AI security standards, guidelines, and reference architectures covering generative AI platforms, LLM-integrated applications, agentic systems, and AI-enabled developer and productivity tooling.
•   Conduct AI security architecture reviews for new and existing AI integrations, including agentic workflows, retrieval-augmented generation (RAG) pipeline designs, LLM API integrations, and multi-model orchestration patterns — identifying risks and defining appropriate mitigations in collaboration with development and platform teams.
•   Build and maintain scalable AI security workflows, assessment playbooks, and decision frameworks that enable the organization to evaluate AI adoption requests efficiently, consistently, and without creating unnecessary friction for business delivery.
•   Define and maintain security requirements for enterprise generative AI platforms, addressing prompt security, data residency, access and identity controls, output handling, audit logging, and integration with IQVIA’s broader identity and data governance controls.
•   Partner with development teams to provide practical AI security guidance, supporting the secure design of AI-integrated applications and ensuring development teams have the guidance, patterns, and standards needed to build responsibly with AI technologies.
•   Support the development of AI security awareness and guidance materials for developers, data teams, and business stakeholders across IQVIA, ensuring consistent understanding of how AI tools should be used within IQVIA’s security and governance framework.
•   Monitor the evolving AI security and regulatory landscape — including emerging attack techniques, model provider disclosures, and developments in AI regulation — and translate findings into timely, actionable updates to IQVIA’s AI governance posture and security standards.
•   Collaborate with Legal, Privacy, and Compliance teams on AI-related regulatory requirements, including obligations under the EU AI Act, GDPR implications of AI data processing, and sector-specific requirements applicable to life sciences and healthcare AI deployments.
•   Define metrics and reporting for AI security governance, providing CISO leadership and governance stakeholders with clear visibility into AI adoption volume, risk profile, assessment coverage, and program maturity across the organization.

Required Experience and Qualifications

•   Substantial progressive experience in Information Security, Security Architecture, or related technical roles, with demonstrated expertise in AI security, cloud security, or application security.
•   Strong working knowledge of generative AI security risks and controls, including prompt injection, data leakage, model abuse, output manipulation, and the supply chain and integration risks associated with third-party AI platforms and APIs.
•   Experience assessing and governing the adoption of enterprise AI and generative AI tools, including productivity platforms such as Microsoft Copilot, developer assistance tools, and LLM-integrated applications and workflows.
•   Familiarity with AI security frameworks and standards including OWASP LLM Top 10 and NIST AI RMF, and working awareness of EU AI Act obligations relevant to enterprise AI governance and security.
•   Experience engaging with governance committees, risk review boards, or cross-functional taskforces as a security subject matter expert, influencing decisions and representing security requirements to non-security stakeholders.
•   Working knowledge of cloud environments (Microsoft Azure and/or Amazon AWS) and the AI and ML services offered within those platforms, with the ability to assess security configurations, data handling behaviors, and integration risks.
•   Experience partnering with development teams, data teams, and business stakeholders to translate security and governance requirements into practical, delivery-compatible guidance and standards.
•   Strong understanding of data protection principles as they apply to AI systems, including data residency, purpose limitation, PHI and PII handling in AI workflows, and cross-border data transfer implications under GDPR and applicable regional regulations.
•   Familiarity with secure architecture patterns for LLM-integrated systems, including RAG pipeline security, agentic system design, prompt workflow controls, and API gateway patterns for model endpoints is preferred.
•   Experience within regulated industries — life sciences, healthcare, or financial services — with awareness of sector-specific compliance and data protection obligations relevant to AI use is preferred.
•   Bachelor’s degree in Computer Science, Information Security, or equivalent practical experience is preferred.
•   Relevant certifications such as CISSP, CISM, CCSP, AWS/Azure Security Specialty, or equivalent are preferred but not mandatory.
•   Strong written and verbal communication skills in English, with the ability to produce governance documentation, security standards, and executive-level reporting across a global, matrixed organization.

IQVIA is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. We create intelligent connections to accelerate the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide. Learn more at https://jobs.iqvia.com

IQVIA is committed to integrity in our hiring process and maintains a zero tolerance policy for candidate fraud. All information and credentials submitted in your application must be truthful and complete. Any false statements, misrepresentations, or material omissions during the recruitment process will result in immediate disqualification of your application, or termination of employment if discovered later, in accordance with applicable law. We appreciate your honesty and professionalism.

About the company

IQVIA is a global provider of advanced analytics, technology solutions, and clinical research services for the life sciences industry. Its services combine deep clinical trial expertise with large datasets and analytics tools, delivered through the Connected Intelligence platform that links the healthcare ecosystem to generate insights while protecting patient privacy. The company differentiates itself by merging clinical research experience with expansive data resources and technology capabilities from its QuintilesIMS lineage, offering an integrated suite for faster research, development, and commercialization of medical treatments. IQVIA’s goal is to help pharmaceutical, biotech, and medical device companies, as well as researchers and governments, accelerate the development of new therapies and improve health outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

Durham, North Carolina

Founded

1998

Get referred to IQVIA

See people who can refer or advise you

Simplify's Take

What believers are saying

IQVIA raised 2026 guidance after Q2 revenue reached $4.368 billion and EBITDA beat targets.
September 3, 2026 Predictive Clinical Development promises 33% faster startup and 50% faster cleaning.
September 2026 refinancing uses $2 billion notes to retire 2026 debt and reduce maturity risk.

What critics are saying

CNIL fined IQVIA Operations France €5 million on May 26, 2026, plus €10,000 daily delays.
IQVIA sued former executives in April 2026, alleging a Syneos-led $180 million client raid.
Repeated privacy breaches could cripple European data products and erode IQVIA's health-data moat.

What makes IQVIA unique

IQVIA combines CRO execution with proprietary health data and commercial intelligence worldwide.
IQVIA.ai, launched March 16, 2026, unifies agentic workflows across clinical, commercial, and real-world operations.
Predictive Clinical Development leverages proprietary data, Prime and Partner sites, and regulated AI.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Life Insurance

Flexible Work Hours

Paid Vacation

Wellness Program

401(k) Retirement Plan

Growth & Insights and Company News

Headcount

6 month growth

↓ -2%

1 year growth

↓ -2%

2 year growth

↓ -1%

Jardal Paintball

Sep 9th, 2026

IQVIA prices $2B senior notes offering to refinance debt and credit facility

IQVIA Holdings announced its subsidiary IQVIA Inc. priced an offering of $2 billion in senior notes due 2034. The notes will bear interest at 6.375% per annum, with semi-annual payments beginning 15 March 2027, and mature on 15 March 2034. Proceeds will be used to redeem the company's senior 5.000% notes due 2026, repay part of its outstanding revolving credit facility debt, and cover offering fees and expenses. The issuance is expected to close on or about 23 September 2026, subject to customary conditions. IQVIA is a global provider of clinical research services, commercial insights, and healthcare intelligence to life sciences and healthcare industries, employing approximately 94,000 people across over 100 countries.

Hyman, Phelps & McNamara, P.C.

Sep 4th, 2026

HPM presenting at IQVIA Annual Controlled substances & State Regulatory Conference (sept. 16-18).

HPM presenting at IQVIA Annual Controlled substances & State Regulatory Conference (sept. 16-18). September 4, 2026 Hyman, Phelps & McNamara, P.C.'s Karla Palmer and Andrew Hull will be speaking again at IQVIA's 28th Annual Controlled Substance & State Regulatory Conference in Scottsdale, AZ (Sept. 16-18). As part of a stacked agenda that runs the gamut on controlled substances issues, Ms. Palmer will speak on compliance considerations for compounders, and Mr. Hull will present on how registrants can mitigate risk and preserve reputation during a DEA investigation. Mr. Hull will also be presenting a course with retired DEA Chief Administrative Law Judge John J. Mulrooney, II, a partner at Belanger Rae & Mulrooney, on protecting your rights in DEA administrative actions. Join FDA Law Blog in Scottsdale for what promises to be another educational conference with key thought leaders and industry experts. Register here. Search FDA Law Blog. Subscribe. Never miss a post from FDA Law Blog

StockTitan

Sep 3rd, 2026

IQVIA's Predictive Clinical Development provides sponsors with significant efficiencies to get treatments to market faster.

IQVIA's Predictive Clinical Development provides sponsors with significant efficiencies to get treatments to market faster. IQVIA introduces an AI-driven clinical development platform that reports sizable time savings from study startup through data cleaning and between trial phases. (Positive) See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google 09/03/2026 - 01:15 PM RESEARCH TRIANGLE PARK, N.C.-(BUSINESS WIRE)- IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, today announced IQVIA Predictive Clinical Development, an AI-powered approach designed to help life sciences sponsors reduce avoidable delays and bring new therapies to patients up to two years faster. Traditional approaches in clinical development no longer keep pace with increasing trial complexity. IQVIA Predictive Clinical Development is built to eliminate them, accelerating every stage of the development lifecycle with measurable results: * 33% faster study startup * 1.7 times more patients recruited from our AI prioritized and Prime & Partner sites with 42% higher enrollment rates * 50% faster data cleaning * 45%+ reduced time between trial phases IQVIA Predictive Clinical Development pairs IQVIA's proprietary data, deep regulatory expertise and best-in-class Healthcare-grade AI(R) with premier technologies from Anthropic, Amazon Web Services (AWS), Databricks, Microsoft, NVIDIA, Palantir and Snowflake orchestrated to drive agentic workflows. "At a time when every moment matters for patients waiting on new therapies, IQVIA Predictive Clinical Development represents a fundamental shift," said Richard Staub, president of Research and Development Solutions at IQVIA. "We're helping customers make development faster, more predictable and of a higher quality - compressing timelines, accelerating decisions and speeding medicines to market." IQVIA Predictive Clinical Development is enabled by IQVIA's clinical AI capabilities: * Clinical Design & Planning Suite generates predictive insights to inform site selection, prioritizes sites including its Prime and Partner network and operationalizes the recruitment strategy to speed enrollment. * Push Button Start-Up is an integrated and streamlined delivery model that applies standardization, automation and AI-enabled processes to accelerate the time to starting patient enrollment. * Real-time Data Cleaning enables faster, more reliable, higher quality data to make confident decisions during and after a study. It brings clinical data together across multiple sources, drives greater efficiency and enables more rapid database locks. IQVIA is uniquely positioned to change the trajectory of clinical development ultimately closing the gap between scientific discovery to patient care. As IQVIA extends its leadership in AI, new components will continue to expand Predictive Clinical Development across the entire development lifecycle, helping customers move faster with confidence. About IQVIA IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA's portfolio of solutions are powered by IQVIA Connected Intelligence(TM) to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI(R), advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 94,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide. IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA's insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com. Kerri Joseph, IQVIA Investor Relations ([email protected]) +1.973.541.3558 Key terms. agentic workflows technical data cleaning technical database locks technical

FinancialContent

Aug 27th, 2026

IQVIA wins multiple industry awards for AI and Technology Innovation across life sciences and healthcare.

IQVIA wins multiple industry awards for AI and Technology Innovation across life sciences and healthcare. August 27, 2026 at 16:15 PM EDT i This article is third-party content and does not represent the views of this site. Tamar Securities, LLC make no guarantees regarding its accuracy or completeness. IQVIA (NYSE: IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced it received recognition this year from multiple independent industry awards programs for its use of AI to help healthcare and life sciences organizations improve decisions, strengthen regulated workflows, protect patient privacy and optimize clinical trial execution. Healthcare and life sciences organizations are under growing pressure to bring therapies to patients faster, make sense of rapidly expanding volumes of data and adopt AI they can trust. The recognized solutions help address these challenges by combining IQVIA's proprietary, expert-curated content and data with deep healthcare and life sciences domain knowledge and extensive experience operating in highly regulated environments where compliance, privacy and data governance are critical. This combination enables customers to turn insight into action with greater speed, precision and accuracy - identifying high-priority patients sooner, accelerating scientific literature reviews, enabling responsible data use at scale, improving regulatory efficiency and strengthening clinical trial supply performance. In addition to its recently announced AI Breakthrough Award for Best Predictive Modeling Solution of the Year, IQVIA has been recognized this year across multiple global technology awards including American Business Awards(R) Gold Stevie(R) for Technical Innovation of the Year - Healthcare Technology - Pharmaceuticals & Biotechnology; MedTech Breakthrough for Best Compliance Solution; American Business Awards(R) Silver Stevie(R) for Healthcare Technology Innovation; and another Silver Stevie(R) for Healthcare & Pharmaceuticals / Product. Granted by independent organizations that review thousands of submissions annually, the awards provide third-party validation of IQVIA's ability to deliver meaningful outcomes across R&D, data privacy, regulatory, trial operations and commercial domains. * American Business Awards(R) Gold Stevie(R)- Technical Innovation of the Year - Healthcare Technology - Pharmaceuticals & Biotechnology: Awarded to IQVIA Literature AI Platform, an agentic system built specifically for scientific literature review that demonstrated 100% recall in search, 93% or higher precision in document screening and more than a 90% reduction in screening workload compared with manual review. The IQVIA Literature AI Platform accelerates the process from search to synthesis while delivering rigorous, traceable outputs aligned with established quality standards. * MedTech Breakthrough - Best Compliance Solution: Awarded to IQVIA's Privacy Analytics Platform, which powers privacy-preserving data use. The technology is deployed within the NHS Federated Data Platform in England, which integrates health data from 55 million patients. The platform has contributed to measurable system impact, including enabling more than 110,000 additional procedures, reducing discharge delays for long-stay patients by 14.9% and supporting more than 90,000 patients in cancer care. * American Business Awards(R) Silver Stevie(R)- Healthcare Technology Innovation: Awarded to IQVIA SmartSolve(R) RIM, an AI-enabled Regulatory Information Management platform. It was recognized for helping accelerate global regulatory approvals, strengthen compliance and improve timely access to healthcare products. * American Business Awards(R) Silver Stevie(R)- Healthcare & Pharmaceuticals / Product: Awarded to the IQVIA Interactive Response Technology (IRT) Supply Automation Value Engine (SAVE) program, which uses real-time analytics and automation to optimize clinical trial drug supply. The program was recognized for reducing instances when trial sites ran out of needed medicines by 76% and cutting drug supply deliveries by 73%. * AI Breakthrough Award - Predictive Modeling Solution of the Year: Awarded to IQVIA's AI-enabled clinical decision support tool, developed in collaboration with Breakthrough T1D. The innovation identifies misdiagnosed and misclassified type 1 diabetes patients. It reduced screening burden by 99.5% - thereby requiring 200 times fewer patient assessments than before. The tool also delivered a ~127x improvement in identifying potential type 1 diabetes patients, with 28% of flagged patients confirmed or suspected to have type 1 diabetes compared with a 0.22% baseline. About IQVIA IQVIA (NYSE: IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA's portfolio of solutions are powered by IQVIA Connected Intelligence(TM) to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI(R), advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 94,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide. IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA's insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com. Contacts. Kerri Joseph, IQVIA Investor Relations ([email protected]) +1.973.541.3558 Alissa Maupin, IQVIA Media Relations ([email protected]) +1.919.923.6785 Report this content If you believe this article contains misleading, harmful, or spam content, please let Tamar Securities, LLC know.

QBeep Intelligent Systems Sdn Bhd

Aug 26th, 2026

IQVIA Korea launches AI platform for smarter physician engagement.

IQVIA Korea launches AI platform for smarter physician engagement. Home / Blog / IQVIA Korea launches AI platform for smarter physician engagement. August 26, 2026 Blog IQVIA Korea has launched MediLens, an AI-powered platform designed to help pharmaceutical and medical-device companies better understand healthcare professionals and sharpen physician engagement. The platform combines scientific and professional data with internal commercial information to generate insights into doctors' research interests, clinical expertise and activities. The move reflects AI's growing role in reshaping healthcare engagement strategies. Could MediLens set a new standard for data-driven physician engagement?

IQVIA

AI Security Architect

About the job